Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2020 | The value of screening biopsies in AL & ATTR amyloidosis

Oliver Charles Cohen • 15 Sep 2020
ISA 2020
Amyloidosis Rare Diseases

Oliver Charles Cohen, MD, University College London Hospitals NHS Foundation Trust, London, UK, talks on the value of screening biopsies in light-chain (AL) and transthyretin (ATTR) amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Oliver Charles Cohen

4:05
Post-renal transplantation hematological response assessment: AL amyloidosis
Oliver Charles Cohen • 16 Sep 2020
4:28
Lenalidomide and Ixazomib: a successful amyloidosis treatment combination?
Oliver Charles Cohen • 14 Sep 2019

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals